![A doctor and a patient looking at a screen](https://www.ema.europa.eu/sites/default/files/styles/ema_carousel/public/2024-06/2024-6_ACT%20EU%20pilots_WEB_homepage-banner.png?itok=-sOPJjH_)
EU collaboration to foster high-quality clinical research
![CHMP highlights pills in different colors on white background](https://www.ema.europa.eu/sites/default/files/styles/ema_carousel/public/2024-01/D10_WEB_CHMP%20highlights_slider%20%28NEW%29.png?itok=gRm_Cj3A)
CHMP recommends 14 new medicines for approval in the EU
![Image of annual report cover showing on laptop, leaflet, ipad, phone](https://www.ema.europa.eu/sites/default/files/styles/ema_carousel/public/2024-05/2024-05_Annual-report-2023-2-_WEB_slider.png?itok=7d5CVHjq)
How we contributed to public and animal health in the European Union
![Person holding a syringe](https://www.ema.europa.eu/sites/default/files/styles/ema_carousel/public/2024-05/2024-05_medical%20devices%20guidance_slider.png?itok=_dE3hGqx)
Q&A document clarifies regulatory requirements for devices used in combination with medicines
![illustration of a laptop with a poll on the screen](https://www.ema.europa.eu/sites/default/files/styles/ema_carousel/public/2024-05/2024-05_EMA-perception-survey_WEB_slider.png?itok=eOG6bLmE)
Have your say and help shape EMA’s future communications. The survey closes on 21 June 2024
![One Health](https://www.ema.europa.eu/sites/default/files/styles/ema_carousel/public/2024-05/2024-05_One%20Health_WEB_Slider.png?itok=3806NLi6)
How to enable EU to prevent and respond to health threats
Find medicine
What's new
FAQs
Latest news
![A doctor and a patient looking at a screen](https://www.ema.europa.eu/sites/default/files/2024-06/2024-6_ACT%20EU%20pilots_WEB_square.png)
Pilots are part of ACT EU collaboration to foster high-quality clinical research in the EU
EMA has issued recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2024.
![medicine pills and tablets](https://www.ema.europa.eu/sites/default/files/2023-11/Web%20image_CHMP_standard_square.png)
EMA’s human medicines committee (CHMP) recommended 14 medicines for approval at its May 2024 meeting
Ixchiq was assessed under the OPEN framework to promote global public health
Durveqtix received support through the PRIority Medicines (PRIME) scheme due to its potential to improve patients’ quality of life
![Annual report 2023 formats](https://www.ema.europa.eu/sites/default/files/2024-05/2024-05_Annual-report-2023-3-_digital_WEB_square%20%281%29.png)
EMA publishes 2023 annual report